Allogeneic Cord Blood-Derived, Dual-Targeting Cd19/Bcma Car-T Cells
Relapsed/Refractory Multiple Myeloma(MM)
Xi'an No.3 HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Relapsed/Refractory Multiple Myeloma(MM) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lcar- F33S Cells Intravenous Infusion Nanjing Legend Biotech Co. | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →